Biotech Values

[DewDiligence]

This thread is about the Copaxone patent case. The best outcome for MNTA is a summary judgment that Teva’s patents are invalid; however, this is rather unlikely insofar as the Judge denied a prior motion by NVS/MNTA for summary judgment based on indefiniteness of the patent specifications.

The next-best outcome for MNTA is a Markman (claims-construction) ruling that weakens Teva’s Copaxone patents and thereby increases the likelihood that the patents will be ruled invalid in a full-fledged legal trial (which has not yet been scheduled).

The worst outcome for MNTA is a summary judgment in Teva’s favor, dismissing NVS/MNTA’s complaint in its entirety, which is highly unlikely, IMO.